Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

Russneft reported for 2023 by RAS

2/14/24 RNFT

Novatek resumes condensate processing in Ust-Luga

2/14/24 NVTK

RusHydro may build the second stage of Sakhalin GRES-2

2/14/24 HYDR

Trust exited UWC with a loss of ₽20 billion

2/14/24 UWGN

Gazprom received technical specifications for connecting the LNG plant in Belarus

2/14/24 GAZP

Trust wants to sell its entire stake in Russneft in 2024

2/14/24 RNFT

Moscow Exchange resumed trading on the stock market

2/14/24 MOEX

Rusal will build an aluminum runway

2/14/24 RUAL

Kamaz publishes strategy until 2030

2/14/24 KMAZ

Moscow Exchange suspends trading on the stock market for the second day in a row

2/14/24 MOEX